CANDEL THERAPEUTICS, INC. Business Development
CANDEL THERAPEUTICS, INC. (CADL) reported Business Development of $13.08 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:BusinessDevelopment · last filed 2026-08-13
- CANDEL THERAPEUTICS, INC. business development for the quarter ending 2026-06-30 was $13.08M, a 328.81% increase year-over-year.
- CANDEL THERAPEUTICS, INC. business development for the quarter ending 2026-03-31 was $4.83M, a 288.27% increase year-over-year.
- CANDEL THERAPEUTICS, INC. business development for the quarter ending 2025-12-31 was $6.59M, a 428.02% increase year-over-year.
- CANDEL THERAPEUTICS, INC. business development for the quarter ending 2025-09-30 was $3.85M, a 74.86% increase year-over-year.
- CANDEL THERAPEUTICS, INC. business development for fiscal 2025 was $14.74M, a 183.64% increase from fiscal 2024.
- CANDEL THERAPEUTICS, INC. business development for fiscal 2024 was $5.20M, a 34.56% decline from fiscal 2023.
- CANDEL THERAPEUTICS, INC. business development for fiscal 2023 was $7.94M.
| Period end | Business Development 3 month | Business Development 6 month | Business Development 9 month | Business Development 12 month |
|---|---|---|---|---|
| 2026-06-30 | $13.08M 10-Q · filed 2026-08-13 | $17.92M 10-Q · filed 2026-08-13 | $24.51M derived: sum of 3 quarters · filed 2026-08-13 | $28.36M derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | $4.83M 10-Q · filed 2026-05-14 | $11.43M derived: sum of 2 quarters · filed 2026-05-14 | $15.28M derived: sum of 3 quarters · filed 2026-05-14 | $18.33M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | $6.59M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $10.44M derived: sum of 2 quarters · filed 2026-03-12 | $13.49M derived: sum of 3 quarters · filed 2026-08-13 | $14.74M 10-K · filed 2026-03-12 |
| 2025-09-30 | $3.85M 10-Q · filed 2025-11-13 | $6.90M derived: sum of 2 quarters · filed 2026-08-13 | $8.14M 10-Q · filed 2025-11-13 | $9.39M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | $3.05M 10-Q · filed 2026-08-13 | $4.30M 10-Q · filed 2026-08-13 | $5.54M derived: sum of 3 quarters · filed 2026-08-13 | $7.75M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | $1.25M 10-Q · filed 2026-05-14 | $2.49M derived: sum of 2 quarters · filed 2026-05-14 | $4.69M derived: sum of 3 quarters · filed 2026-05-14 | $5.62M derived: sum of 4 quarters · filed 2026-05-14 |
| 2024-12-31 | $1.25M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $3.45M derived: sum of 2 quarters · filed 2026-03-12 | $4.37M derived: sum of 3 quarters · filed 2026-03-12 | $5.20M 10-K · filed 2026-03-12 |
| 2024-09-30 | $2.20M 10-Q · filed 2025-11-13 | $3.12M derived: sum of 2 quarters · filed 2025-11-13 | $3.95M 10-Q · filed 2025-11-13 | |
| 2024-06-30 | $921.00K 10-Q · filed 2025-08-14 | $1.75M 10-Q · filed 2025-08-14 | ||
| 2024-03-31 | $826.00K 10-Q · filed 2025-05-13 | |||
| 2023-12-31 | $7.94M 10-K · filed 2025-03-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |